BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Executive Chair Transition

Tango Therapeutics (TNGX)Tango TherapeuticsCompany update

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of

Related news

TNGXTango Therapeutics2026-09-03 20:05 EST

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNGXTango Therapeutics2026-09-01 11:00 EST

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

CGEMCullinan Therapeutics, Inc.2026-09-21 16:00 EST

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

FATEFate Therapeutics2026-09-16 11:00 EST

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

ELVNEnliven Therapeutics2026-09-03 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

RLAYRelay Therapeutics2026-09-01 20:46 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-09-03 20:05 EST

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNGXTango Therapeutics2026-09-01 11:00 EST

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Stock data

Close
21.75 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States